Compare Hilton Hotels Corporation Common Stock (HLT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Hilton Hotels Corporation Common Stock trades at $326.4 (market cap $73.63B), while State Street SPDR S&P Biotech ETF trades at $153.98. The key difference: Hilton Hotels Corporation Common Stock pays a 0.19% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Hilton Hotels Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| HLT | XBI | |
|---|---|---|
Market Cap | $73.63B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $350.22 | $164.28 |
52-Week Low | $256.75 | $85.16 |
Enterprise Value | $86.12B | — |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $323.22, up 0.59% with a bearish technical signal despite consistent earnings beats. The company shows strong fundamentals with 2025 revenue of $12.04B and net income of $1.46B, though valuation metrics appear elevated with a P/E of 49.06. Recent developments include brand expansion initiatives and upcoming Q2 2026 earnings on July 28, 2026.
Wall Street maintains a bullish outlook with 55% buy ratings and a $345.18 price target, representing 6.8% upside. Key risks include rising debt levels (debt-to-asset ratio increased to 73.88% in 2025) and technical weakness. The stock offers growth potential through Hilton's brand expansion but faces headwinds from high valuation and negative shareholder equity.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
